Link to Full Article Armata’s bacteriophage, AP-PA01, used to treat multidrug-resistant Pseudomonas aeruginosa infection Paper appears in the peer-reviewed journal Infection Company to host bacteriophage Key Opinion Leader meeting and live webcast on Wednesday, June 26 MARINA DEL REY, Calif, May 28, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely […]

Link to Article SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that its stockholders voted to approve the proposals required to complete the business combination with C3J Therapeutics at a special meeting of AmpliPhi Biosciences stockholders held earlier today. Approximately […]

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhi’s extensive phage library and Phase 1/2-ready asset with C3J’s expertise in synthetic phage and broad preclinical pipeline $10 million to be invested by existing C3J shareholders upon closing The companies plan to hold a joint conference call on […]

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback  Announced positive updated results from the company’s expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% treatment success at the end of therapy  Raised gross proceeds of $6.8 million through an […]